Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Anno...

Your unfiltered news center. ®

The world you see depends upon the news you get. ®

HOME

ARTS

RSS

Today's Date: June 3, 2023

New PATHFINDER Study Analysis Demonstrates Efficient Diagnostic Resolution Following Multi-Cancer Early Detection Testing • Bijou Ikli named new CEO by Florida Assisted Living Association • LYNPARZA® (olaparib) and IMFINZI® (durvalumab) combination reduced risk of disease progression or death by 37% vs. chemo • Promoting Diversity and Equity in Cancer Research, Women Leaders in Oncology® and Vaniam Group Announce Recipients of 2023 Y • Exai Bio Presents New Multi-Cancer Early Detection Data at the American Society of Clinical Oncology (ASCO) 2023 Annual Meeting • Air Canada's Inaugural Amsterdam-Montreal Route Takes Off; Uplifts Sustainable Aviation Fuel in Amsterdam • High Schooler empowers Youth with Nonprofit "Unlimited Potential", raises $100,000 for Sports Medicine Research and Advocacy • UNice Celebrates LGBTQ Pride Month • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i • GRAIL Presents Real-World Experience With The Galleri® Multi-Cancer Early Detection Test At 2023 ASCO Annual Meeting • Statement from Minister Hutchings on progress in support of rural Canadians • Merck’s KEYTRUDA® (pembrolizumab) Plus Chemotherapy Before Surgery and Continued as a Single Agent After Surgery • Preliminary Ongoing Results with CYT-0851 in Combination with Capecitabine or Gemcitabine in Advanced Solid Tumors Show Early Cl • KEYTRUDA® (pembrolizumab) Plus Chemotherapy Significantly Improved Overall Survival Versus Chemotherapy Alone as First-Line • 56 Trilogy Health Services Communities Earn 2023 AHCA/NCAL Bronze National Quality Award • San Francisco Pride Announces Headliners Hayley Kiyoko and Princess Nokia for 53rd Annual SF Pride Parade & Celebration Feat • Government of Canada releases summary of actions taken to address the safety and wellbeing of Indigenous women, girls and 2SLGBT • Statement by the Prime Minister to mark four years since the publication of the final report of the National Inquiry into Missin • Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Continues Investigation of SentinelOne, Inc. (S) on Behalf • Gilead and Arcus Announce Anti-TIGIT Domvanalimab Continues to Demonstrate Consistent Improvement in Progression-Free Survival i

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Cutera, Inc. (CUTR) on Behalf o

LOS ANGELES , May 26 /Businesswire/ - Glancy Prongay & Murray LLP (“GPM”), a leading national shareholder rights law firm, today announced that it has commenced an investigation on behalf of Cutera, Inc. (“Cutera” or the “Company”) (NASDAQ: CUTR) investors concerning the Company’s possible violations of the federal securities laws.

If you suffered a loss on your Cutera investments or would like to inquire about potentially pursuing claims to recover your loss under the federal securities laws, you can submit your contact information at www.glancylaw.com/cases/Cutera-Inc/. You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at shareholders@glancylaw.com to learn more about your rights.

On February 28, 2023, after the market closed, Cutera announced that it was unable to timely file its 2022 Annual Report. The Company also disclosed that it had identified “material weaknesses in its internal control over financial reporting related to ineffective information technology general controls and ineffective inventory count controls.” On this news, Cutera’s stock price fell $0.32, or 1%, to close at $32.11 per share on March 1, 2023.

Then, on March 16, 2023, Cutera disclosed that it had identified additional material weaknesses related to stock-based compensation. On this news, Cutera’s stock price fell $3.49, or 12.5%, to close at $25.36 per share on March 17, 2023.

Then, on April 7, 2023, the Company announced that its Executive Chairman and Chairman of the Board had demanded a special meeting of the Company’s stockholders to vote on the removal of five members of the Company’s Board.

On April 12, 2023, Cutera revealed that it terminated the Company’s Executive Chairman and Chairman of the Board, as well as the Company’s Chief Executive Officer. In connection with this announcement, Cutera also withdrew its full-year 2023 financial guidance. On this news, Cutera’s stock price fell $7.63, or 28.1%, to close at $19.44 per share on April 12, 2023.

Then, on May 9, 2023, Cutera reported disappointing financial results for the first quarter 2023, stating that it was “below expectations due to execution challenges in the business.” Furthermore, the Company announced that its Chief Financial Officer had resigned. On this news, Cutera’s stock price fell $6.06, or 30%, to close at $14.14 per share on May 11, 2023, thereby injuring investors further.

Whistleblower Notice: Persons with non-public information regarding Cutera should consider their options to aid the investigation or take advantage of the SEC Whistleblower Program. Under the program, whistleblowers who provide original information may receive rewards totaling up to 30 percent of any successful recovery made by the SEC. For more information, call Charles H. Linehan at 310-201-9150 or 888-773-9224 or email shareholders@glancylaw.com.

About GPM

Glancy Prongay & Murray LLP is a premier law firm representing investors and consumers in securities litigation and other complex class action litigation. ISS Securities Class Action Services has consistently ranked GPM in its annual SCAS Top 50 Report. In 2018, GPM was ranked a top five law firm in number of securities class action settlements, and a top six law firm for total dollar size of settlements. With four offices across the country, GPM’s nearly 40 attorneys have won groundbreaking rulings and recovered billions of dollars for investors and consumers in securities, antitrust, consumer, and employment class actions. GPM’s lawyers have handled cases covering a wide spectrum of corporate misconduct including cases involving financial restatements, internal control weaknesses, earnings management, fraudulent earnings guidance and forward looking statements, auditor misconduct, insider trading, violations of FDA regulations, actions resulting in FDA and DOJ investigations, and many other forms of corporate misconduct. GPM’s attorneys have worked on securities cases relating to nearly all industries and sectors in the financial markets, including, energy, consumer discretionary, consumer staples, real estate and REITs, financial, insurance, information technology, health care, biotech, cryptocurrency, medical devices, and many more. GPM’s past successes have been widely covered by leading news and industry publications such as The Wall Street Journal, The Financial Times, Bloomberg Businessweek, Reuters, the Associated Press, Barron’s, Investor’s Business Daily, Forbes, and Money.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.